Dr. Adams on Whether Prior Lines of Therapy Impact Response to Immunotherapy in TNBC
September 13th 2018Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, NYU Langone’s Perlmutter Cancer Center, discusses whether the number of prior lines of therapy impact response to immunotherapy in patients with triple-negative breast cancer (TNBC).
Read More
Dr. Adams on Combinatorial Approaches in Triple-Negative Breast Cancer
August 1st 2018Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, NYU Langone’s Perlmutter Cancer Center, discusses combinatorial approaches in triple-negative breast cancer.
Read More
Dr. Adams on Immunotherapy in Triple-Negative Breast Cancer
July 3rd 2018Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, New York University Langone’s Perlmutter Cancer Center, discusses immunotherapy in triple-negative breast cancer (TNBC).
Read More